Preclinical development of cancer stem cell drugs

Jiangbing Zhou, Ying Zhang

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Background: Despite recent progress in cancer treatment, the current cancer chemotherapy can mainly produce remission but often fails to cure cancer due to the existence of cancer stem cells. The emerging cancer stem cell hypothesis offers new insight into the failure of current cancer drugs and suggests new approaches for improved understanding of cancer biology and cancer drug development. Objective: In this review, we discuss the concept of cancer stem cells, origin of cancer stem cells and different approaches for isolating or enriching cancer stem cells. We also review the resistance of cancer stem cells to standard chemotherapy and radiation therapy and potential mechanisms for the resistance. Finally, based on the current knowledge on cancer stem cells, we discuss potential approaches for developing new drugs that target cancer stem cells and propose new methods for evaluation of cancer stem cell drugs. Conclusion: Improved cancer treatment is likely to be achieved by a combination of drugs that kill both replicating cancer cells and more quiescent cancer stem cells.

Original languageEnglish (US)
Pages (from-to)741-752
Number of pages12
JournalExpert Opinion on Drug Discovery
Issue number7
StatePublished - Jul 2009
Externally publishedYes


  • Cancer stem cells
  • Chemotherapy
  • Drug development
  • Drug resistance
  • Preclinical model

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'Preclinical development of cancer stem cell drugs'. Together they form a unique fingerprint.

Cite this